Investor Presentaiton slide image

Investor Presentaiton

IPM Indian Pharmaceutical Market Source: Iqvia, MAT 400 300 200 100 Q2 India Sales Q2 (Rs. Cr.) 27% 248 20% Consistently Exceeding IPM Growth 15% 16% 10% 5% 11% 11% 13% 0% Mar-19 Mar-20 314 Q2 FY22 Q2 FY23 4% 8% Mar-21 ■IPM Ajanta Pharma India Sales IQVIA Sep. MAT 2022 Derma 20% Pain 8% Cardio 41% Opthal 31% 18% 18% 7% Gwth 2X of the market 14% Mar-22 Sep-22 700 H1 India Sales-H1 (Rs. cr.) 24% 600 500 477 400 IQVIA Sep. MAT 2021 300 Pain 8% Derma 21% Cardio 200 43% 100 Opthal 29% H1 FY22 593 ■H1 FY23 ajanta 11 of 37 ajanta 12 of 37 6
View entire presentation